Integrin-FAK Inhibitors: FAK
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
PI3K/AKT/mTOR Pathway Inhibitors: pan-PI3K
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
PI3K/AKT/mTOR Pathway Inhibitors: AKT
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
PI3K/AKT/mTOR Pathway Inhibitors: mTOR
Neo adjuvant (before surgery) and first-line treatment with/without extended (maintenance) treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Overall Survival (months)
The length of time where half the patients in the study are still alive
Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Partially Pt-Sensitive/Resistant: Treatment given for recurrence occurring 6-12 months or less than 6 months after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
RAS/RAF/MAPK Pathway Inhibitors: RAF/MEK
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
RAS/RAF/MAPK Pathway Inhibitors: MEK
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
JAK/STAT Inhibitors: STAT3
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Integrin-FAK Inhibitors: FAK
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT04625270: RAMP 201 | II | Avutometinib, Defactinib | A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | The combination of avutometinib with defactinib yields encouraging response rates with a well tolerated safety profile in women with heavily pretreated recurrent LGSOC regardless of KRAS status and with prior MEK inhibitor treatment Avu+Def vs Avu: ORR: 45 vs 10% KRAS MUT: KRAS WT: abs Jun 2023 and poster, abs Mar 2024 |
| NCT01778803 | I | Defactinib, Paclitaxel | A Phase I/Ib Study of Paclitaxel in Combination With VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Advanced Ovarian Cancer | Defactinib + weekly paclitaxel is well tolerated and showed promising activity ORR: 18.2% abs May 2014 and poster |
| NCT03875820; FRAME | I | Defactinib, Avutometinib | FRAME: A Phase I Trial of the Combination of Defactinib (VS-6063) (FAK Inhibitor) and VS-6766 (RO5126766) (CH5126776) (a Dual RAF/MEK Inhibitor) in Patients With Advanced Solid Tumours | VS-6766 (CH5127677)+defactinib shows promising clinical activity in patients with LGSOC including those who have been previously treated with a MEK inhibitor ORR: 46% abs Apr 2021 and poster, abs Sep 2021 |
PI3K/AKT/mTOR Pathway Inhibitors: pan-PI3K
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT01363232 | I | Binimetinib, Buparlisib | A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors | Buparlisib+binimetinib shows encouraging efficacy in RAS/RAF MUT ovarian cancer patients, but with significant toxicity ORR: 27.8% Pub 2020 |
PI3K/AKT/mTOR Pathway Inhibitors: AKT
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT01653912 | I/II | Afuresertib, Carboplatin, Paclitaxel | An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer | Afuresertib mediated AKT kinase inhibition in combination with carboplatin+paclitaxel demonstrates promising efficacy in platinum resistant ovarian cancer ORR: 32.1% pub 2019 |
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02338622 | I | Olaparib, Capivasertib | A Phase I Multi-centre Trial of the Combination of Olaparib (PARP Inhibitor) and AZD5363 (AKT Inhibitor) in Patients With Advanced Solid Tumours | Capivasertib+olaparib is safe and tolerable and anti-tumor activity is observed in patients harboring tumors with BRCA MUT and BRCA WT cancers with or without somatic DDR and/or PI3K-AKT pathway alterations ORR: 24% pub 2020 |
PI3K/AKT/mTOR Pathway Inhibitors: mTOR
Neo adjuvant (before surgery) and first-line treatment with/without extended (maintenance) treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT01579812 | II | Carboplatin, Metformin, Paclitaxel | A Phase II Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Metformin treatment before surgery and added to first-line chemotherapy is well tolerated and is associated with a better than expected OS, particularly in patients with stage II-III disease PFS: 18.0 months pub 2020 |
First-line treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| IRCT2016- 022726788N1 | II | Carboplatin, Metformin, Paclitaxel | Evaluation of the clinical efficacy of adding metformin to chemotherapy regimen for patients with ovarian cancers | Improved RFS with addition of metformin to carboplatin+paclitaxel in stage I-III patients CarboPt+Pac+Met vs CarboPt+Pac: RFS: 48.0 vs 25.7 months pub 2018 |
Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT01010126 | II | Temsirolimus, Bevacizumab | A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer | Temsirolimus+bevacizumab has activity in platinum sensitive ovarian cancer but with substantial toxicity ORR: 24% abs Jun 2013 and poster |
| NCT01031381 | II | Everolimus, Bevacizumab | Phase II Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer An Investigator-initiated, Single-institution Trial at Magee-Womens Hospital | Everolimus+bevacizumab does not improve responses compared to bevacizumab alone in Pt-S ovarian cancer patients, but selected patients with alterations in the PI3K/mTOR pathway may have benefit ORR: 16.7% pub 2020 |
Partially Pt-Sensitive/Resistant: Treatment given for recurrence occurring 6-12 months or less than 6 months after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT00429793 | II | Temsirolimus | A Phase II Evaluation of CCI-779 (Temsirolimus, NCI-Supplied Agent, NSC #683864, IND #61010) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma | Temsirolimus has modest activity, but phase III not warranted in unselected patients; CCND1 positivity associated with longer PFS ORR: 9.3% pub 2011 |
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT01010126 | II | Temsirolimus, Bevacizumab | A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer | Temsirolimus+bevacizumab has activity in platinum resistant ovarian cancer but with substantial toxicity ORR: 32.1% abs Jun 2013 and poster |
| NCT01031381 | II | Everolimus, Bevacizumab | Phase II Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer An Investigator-initiated, Single-institution Trial at Magee-Womens Hospital | Everolimus+bevacizumab does not improve responses compared to bevacizumab alone in Pt-R ovarian cancer patients, but selected patients with alterations in the PI3K/mTOR pathway may have benefit ORR: 11.1% pub 2020 |
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02283658 | II | Everolimus, Letrozole | A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas | Everolimus+letrozole combination shows promising results in ER-positive ovarian cancer PFS: 3.9 months pub 2017 |
PI3K/AKT/mTOR Pathway Inhibitors: TORC 1/2
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02193633 | I | Paclitaxel, Vistusertib | TAX-TORC: A Phase I Multi-centre Trial of the Combination of AZD2014 (Dual mTORC1 and mTORC2 Inhibitor) and Weekly Paclitaxel in Patients With Solid Tumours | Vistusertib+paclitaxel combination has promising anti-tumor activity 25 evaluable ovarian: pub 2018 |
RAS/RAF/MAPK Pathway Inhibitors: RAF/MEK
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT04625270: RAMP 201 | II | Avutometinib, Defactinib | A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | The combination of avutometinib with defactinib yields encouraging response rates with a well tolerated safety profile in women with heavily pretreated recurrent LGSOC regardless of KRAS status and with prior MEK inhibitor treatment Avu+Def vs Avu: ORR: 45 vs 10% KRAS MUT: KRAS WT: abs Jun 2023 and poster, abs Mar 2024 |
| NCT03875820; FRAME | I | Avutometinib, Defactinib | FRAME: A Phase I Trial of the Combination of Defactinib (VS-6063) (FAK Inhibitor) and VS-6766 (RO5126766) (CH5126776) (a Dual RAF/MEK Inhibitor) in Patients With Advanced Solid Tumours | Avutometinib (VS-6766)+defactinib shows promising clinical activity in patients with LGSOC including those who have been previously treated with a MEK inhibitor ORR: 46% abs Apr 2021 and poster, abs Sep 2021 |
RAS/RAF/MAPK Pathway Inhibitors: MEK
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT01849874; MILO/ENGOT-OV11 | III | Binimetinib, Liposomal doxorubicin, Paclitaxel, Topotecan | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Binimetinib shows activity in LGSOC, but chemotherapy responses were higher than expected; higher response rates and longer PFS were seen in patients treated with binimetinib who harbored MAPK pathway mutations, most commonly in KRAS Bin vs TPC (Pac, PLD or Top): ORR: 24 vs 24% Bin: w/ MAPK pathway alterations vs w/o MAPK pathway alterations: pub 2020, 2023 |
| NCT02101788; GOG-281/LOGS | III | Letrozole, Liposomal doxorubicin, Paclitaxel, Tamoxifen, Topotecan, Trametinib | A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer | In LGSOC, trametinib is associated with significantly improved ORR and PFS compared to standard of care Tra vs TPC (Let, Pac, PLD, Tam or Top): ORR: 26.2 vs 6.2%* pub 2022 |
| NCT00551070 | II | Selumetinib | A Phase II Trial of AZD6244 (NSC# 748727) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum | Selumetinib has promising activity in patients with low grade serous ovarian cancer; no significant correlation of response with BRAF or RAS mutations, but analysis performed on primary tumor specimens ORR: 15.4% pub 2013 |
| NCT01363232 | I | Binimetinib, Buparlisib | A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors | Binimetinib+buparlisib shows encouraging efficacy in RAS/RAF MUT ovarian cancer patients, but with significant toxicity ORR: 27.8% Pub 2020 |
JAK/STAT Inhibitors: STAT3
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT01325441 | II | Napabucasin, Paclitaxel | A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | Promising responses to napabucasin+paclitaxel in heavily pretreated patients ORR: 20% abs Jun 2016; Jun 2017 |